Cramer's Morning Take: Bristol Meyers 2/6/25

Jim and Jeff dive into the latest profit guidance for Bristol Meyers, exploring its impact on investor sentiment. They analyze the pharmaceutical industry's recent trends, focusing on companies like Eli Lilly. The discussion includes financial results and innovative drug solutions, such as weight loss medications and treatments for schizophrenia. Their insights reveal key market strategies and the societal implications of these developments, providing listeners with a comprehensive view of current opportunities in the sector.